Fidelis Capital Partners LLC Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fidelis Capital Partners LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 918 shares of the company’s stock after purchasing an additional 347 shares during the quarter. Fidelis Capital Partners LLC’s holdings in IDEXX Laboratories were worth $510,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC boosted its stake in shares of IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after purchasing an additional 7,441,162 shares during the period. Alliancebernstein L.P. lifted its holdings in IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after buying an additional 214,529 shares in the last quarter. Geode Capital Management LLC lifted its holdings in IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock valued at $971,569,000 after buying an additional 26,197 shares in the last quarter. Blair William & Co. IL lifted its holdings in IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after buying an additional 7,812 shares in the last quarter. Finally, Brown Advisory Inc. lifted its holdings in IDEXX Laboratories by 2.2% during the 3rd quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company’s stock valued at $507,725,000 after buying an additional 24,741 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX traded down $2.30 during trading hours on Friday, hitting $475.49. The stock had a trading volume of 92,792 shares, compared to its average volume of 422,732. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The firm has a 50-day moving average price of $539.94 and a 200 day moving average price of $508.49. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The firm has a market capitalization of $39.49 billion, a price-to-earnings ratio of 47.45, a PEG ratio of 3.68 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the previous year, the business posted $2.05 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,524 shares of company stock worth $24,871,960. Company insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group boosted their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. boosted their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Barclays boosted their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research note on Tuesday, January 30th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $591.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.